Italy: Epsilen Bio acquired by Chroma Medicine, which launches with US$125m in financing

Epsilen Bio, a biotechnology company developing transformative therapies through targeted epigenetic silencing of genes, has announced its acquisition by Chroma Medicine, which launches with US$125m in total financing. Atlas Venture and Newpath Partners seeded the US company with participation from Sofinnova Partners. The Series A was led by Cormorant Asset Management with participation by Casdin…